These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 18713565)
21. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Hawker K Curr Opin Neurol; 2008 Apr; 21 Suppl 1():S19-25. PubMed ID: 18388796 [TBL] [Abstract][Full Text] [Related]
22. B-cell-directed therapy for inflammatory skin diseases. Nagel A; Hertl M; Eming R J Invest Dermatol; 2009 Feb; 129(2):289-301. PubMed ID: 19148218 [TBL] [Abstract][Full Text] [Related]
23. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972 [TBL] [Abstract][Full Text] [Related]
24. [Rituximab: a original biotherapy in auto-immune disorders]. Sibilia J; Sordet C Rev Med Interne; 2005 Jun; 26(6):485-500. PubMed ID: 15936477 [TBL] [Abstract][Full Text] [Related]
25. [Immunologic effects of anti-B-lymphocyte antibodies]. Cartron G Rev Med Interne; 2005 Oct; 26 Spec No 1():42-6. PubMed ID: 16475265 [No Abstract] [Full Text] [Related]
26. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389 [TBL] [Abstract][Full Text] [Related]
27. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. Studer V; Rossi S; Motta C; Buttari F; Centonze D J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066 [TBL] [Abstract][Full Text] [Related]
28. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647 [TBL] [Abstract][Full Text] [Related]
29. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. McLaughlin KA; Wucherpfennig KW Adv Immunol; 2008; 98():121-49. PubMed ID: 18772005 [TBL] [Abstract][Full Text] [Related]
30. CD20 as a target for therapeutic type I and II monoclonal antibodies. Beers SA; Chan CH; French RR; Cragg MS; Glennie MJ Semin Hematol; 2010 Apr; 47(2):107-14. PubMed ID: 20350657 [TBL] [Abstract][Full Text] [Related]
31. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date. Ancau M; Berthele A; Hemmer B Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436 [TBL] [Abstract][Full Text] [Related]
32. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. Mease PJ J Rheumatol; 2008 Jul; 35(7):1245-55. PubMed ID: 18609733 [TBL] [Abstract][Full Text] [Related]
33. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence. Kinzel S; Weber MS CNS Drugs; 2016 Dec; 30(12):1137-1148. PubMed ID: 27844213 [TBL] [Abstract][Full Text] [Related]
34. Treatment of SLE with anti-CD20 monoclonal antibody. Looney RJ; Anolik J; Sanz I Curr Dir Autoimmun; 2005; 8():193-205. PubMed ID: 15564722 [TBL] [Abstract][Full Text] [Related]